Assessment of safety of product
- Registration Number
- CTRI/2024/01/061021
- Lead Sponsor
- FemiCura HealthTech Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Female and male Asian Indian subjects.
2. Healthy Human subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup)
3. Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)
1. For female: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
2. Having refused to give his or her assent by not signing the consent form
3. Taking part in another study liable to interfere with this study
4. Being diabetic.
5. Being asthmatic.
6. Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
7. Having cutaneous hypersensitivity (except in the case of studies with evaluation of sensitive skin).
8. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
9. Having undergone a surgery requiring a general anaesthesia of more than one hour in the past 6 months.
10. Having changed his or her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.
11. The day of the patch application: no cosmetic product must be used (test site clean with water only).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sensitization potentialTimepoint: Day 3, Day 5, Day 7, Day 10, Day 12, Day 14, Day 17, Day 19, Day 21, Day 38, Day 39, Day 40
- Secondary Outcome Measures
Name Time Method ilTimepoint: NA